Sector: MedicalImmunoGen, Inc. (NASDAQ: IMGN)
Ranking History
Scan Date: | 11/10/2009 |
Sector: | Medical |
Funamental : | 232 |
Technical : | 17 |
Performance : | 171 |
Overall: | 138 |
Number of Stocks: | 306 |
Scan Date: | 11/3/2009 |
Sector: | Medical |
Funamental : | 254 |
Technical : | 158 |
Performance : | 264 |
Overall: | 272 |
Number of Stocks: | 306 |
Scan Date: | 10/27/2009 |
Sector: | Medical |
Funamental : | 278 |
Technical : | 55 |
Performance : | 268 |
Overall: | 249 |
Number of Stocks: | 306 |
Headlines
- ImmunoGen, Inc. Announces Second License Taken by Amgen for Right to Use the Company's TAP Technology
Nov 19, 2009 04:01 PM | AMGN, IMGN
- ImmunoGen, Inc. Announces Encouraging Clinical Data with Its IMGN901 Compound in the Treatment of Merkel Cell Carcinoma
Nov 17, 2009 12:31 PM | IMGN
- ImmunoGen, Inc. Announces Election of Howard Pien to its Board of Directors and Other Results from its Annual Meeting of Shareholders
Nov 11, 2009 01:45 PM | IMGN, SMSC
- Investing In The Biotech Sector: Here’s An Easy Way To Profit From Biotech Stocks
Nov 11, 2009 10:44 AM | ARIA, BBI, BMRN, BMY, CELG, IMGN
- ImmunoGen, Inc. Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Nov 10, 2009 06:30 AM | IMGN
- ImmunoGen, Inc. Reports First Quarter Fiscal Year 2010 Financial Results
Oct 29, 2009 04:01 PM | IMGN
- ImmunoGen, Inc. Announces Webcast of Presentation at the Oppenheimer 20th Annual Healthcare Conference
Oct 27, 2009 06:30 AM | IMGN
- Get Instant Biotech Diversification
Oct 22, 2009 01:09 PM | AMGN, BBI, GENZ, IMGN
- ImmunoGen, Inc. Announces Conference Call to Discuss its First Quarter Fiscal Year 2010 Financial Results
Oct 22, 2009 06:30 AM | IMGN
- ImmunoGen Announces Amgen has Licensed Rights to Use the Company's TAP Technology for a Solid Tumor Target
Sep 16, 2009 04:01 PM | AMGN, IMGN
- ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2009 Financial Results
Aug 06, 2009 04:10 PM | IMGN
- ImmunoGen, Inc. Announces Webcast of Presentation at the 29th Annual Canaccord Adams Global Growth Conference
Aug 05, 2009 10:19 AM | IMGN
- ImmunoGen Announces Encouraging New Clinical Data with the Company’s IMGN901 Compound in the Treatment of Small-Cell Lung Cancer
Jul 31, 2009 10:31 PM | IMGN
- ImmunoGen, Inc. Announces Conference Call to Discuss its Fourth Quarter and Fiscal Year 2009 Financial Results
Jul 30, 2009 06:31 AM | IMGN
- ImmunoGen, Inc. Announces Completion of Public Offering of Common Stock
Jun 23, 2009 04:05 PM | IMGN
- ImmunoGen, Inc. Announces Exercise of Over-Allotment Option
Jun 22, 2009 09:53 AM | AMGN, IMGN
- ImmunoGen, Inc. Prices Public Offering of Common Stock
Jun 18, 2009 09:21 AM | IMGN
- ImmunoGen, Inc. Announces Proposed Public Offering of Common Stock
Jun 17, 2009 04:06 PM | IMGN
- ImmunoGen, Inc. Elects to Discontinue Further Internal Development of Its IMGN242 Compound
Jun 11, 2009 04:04 PM | IMGN
- ImmunoGen, Inc. Announces Encouraging Trastuzumab-DM1 Phase II Clinical Findings Presented at ASCO
May 30, 2009 08:03 AM | IMGN
- Form 4 IMMUNOGEN INC For: Nov 18 Filed by: LAMBERT JOHN (10K)
Nov 20, 2009 05:52 PM
- Form 4 IMMUNOGEN INC For: Nov 11 Filed by: PIEN HOWARD H (10K)
Nov 13, 2009 12:10 PM
- Form 3 IMMUNOGEN INC For: Nov 11 Filed by: PIEN HOWARD H (10K)
Nov 13, 2009 12:08 PM
- Form 4 IMMUNOGEN INC For: Nov 11 Filed by: MCCLUSKI STEPHEN C (10K)
Nov 13, 2009 12:04 PM
- Form 4 IMMUNOGEN INC For: Nov 11 Filed by: SAYARE MITCHEL (10K)
Nov 12, 2009 04:02 PM
- Form 4 IMMUNOGEN INC For: Nov 11 Filed by: Wallace Richard John (10K)
Nov 12, 2009 04:01 PM
- Form 4 IMMUNOGEN INC For: Nov 11 Filed by: ONETTO NICOLE (10K)
Nov 12, 2009 04:01 PM
- Form 4 IMMUNOGEN INC For: Nov 11 Filed by: SKALETSKY MARK B (10K)
Nov 12, 2009 04:01 PM
- Form 4 IMMUNOGEN INC For: Nov 11 Filed by: VILLAFRANCA JOSEPH J (10K)
Nov 12, 2009 04:01 PM
- Form 4 SAYARE MITCHEL For: Nov 05 (10K)
Nov 09, 2009 09:56 AM
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
IMGN
|
Compare to S&P
|
| YTD |
93.01 %
|
59.43 %
|
| 4 Weeks |
3.37 %
|
2.82 %
|
| 12 Weeks |
10.25 %
|
3.46 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: -4.76 %
|
|
EPS Growth in Last Year: -15.79 %
|
|
Sales Growth in Last Quarter: -27.96 %
|
|
Sales Growth in Last Quarter: -49.41 %
|
|
